Feature | May 30, 2013| Kamran Zamanian, Ph.D., and Jefferson Harding, B.Sc., MA

Market Drivers for U.S. PTCA and Cutting Balloon Catheters

Boston Scientific, Apex, balloon catheter

Boston Scientific's Apex PTCA dilatation balloon catheter.

The AngioScore Angiosculpt PTA scoring balloon used to crack heavily calcified lesions.

Interventional cardiology treats cardiovascular disease, an illness currently afflicting one in every three Americans. Its affects range from high-blood pressure to a fatal stroke.  Percutaneous transluminal coronary angioplasty (PTCA) balloon catheters were the first devices used in the field of interventional cardiology. The growth of the stent market, which is the largest segment for interventional cardiology devices, has helped to fuel the sales of PTCA balloons. In addition, this market is driven by U.S. Food and Drug Administration (FDA) policy, pre-/post-stent dilations and plaque debulking.

PTCA and Cutting Balloon Catheters Market

The total U.S. market for PTCA and cutting balloon catheters was valued at $293.5 million in 2012. The PTCA balloon segment accounted for close to 90 percent of the total coronary balloon catheter market, with cutting balloons accounting for the remaining portion. The PTCA balloon catheter market is expected to increase over the next few years and the cutting balloon market is expected to experience a slight decrease. The number of percutaneous coronary intervention (PCI) procedures is the primary market driver as a moderate decrease in the average selling price of devices is expected.

There are several market drivers:

Changes in FDA Policy

In 2010, the FDA downgraded standard balloon-tipped angioplasty catheters from Class III medical devices to Class II devices with special controls. What this means is that companies can now bring balloon catheters to market through the 510(k) clearance process rather than the pre-market approval (PMA) process. A 510(k) device only needs to prove that it is similar enough to a previously approved device in order to receive FDA approval. The PMA process requires either a clinical trial or additional laboratory studies in order to receive FDA approval and is a much longer process than 510(k). This influences the market such that companies will be able to receive clearance for their devices faster and will be more likely to attempt to enter this market because of the shorter, less expensive approval time. This change in policy has the potential to significantly alter the competitive landscape and drive product innovation through increased competition.

Pre-/Post- Stent Dilations

The majority of PTCA balloon catheters are used in order to dilate a vessel before inserting a stent. Concerns about late-stent thrombosis have also had a positive effect on the number of pre-stent dilation procedures preformed. Additionally, PTCA balloon catheters may be used for confirming proper deployment and placement of self-expanding stents, and their increased use during those procedures is also having a positive effect on unit growth.

Plaque Debulking

Cutting and scoring balloons are used as an auxiliary method for plaque debulking. These devices have small blades or abrasive surfaces attached to the balloon in order to aid in the dissection of calcified lesions. While cutting balloons are predicted to gradually represent less of the total coronary balloon catheter market over the next few years, they have expanded the number of cases that can benefit from their use, which has had a positive effect on unit sales.

Competitor Analysis

In 2012, Boston Scientific was the leading competitor in the total PTCA and cutting balloon catheter market, with more than half of the market share. The company continues to dominate the cutting balloon catheter market with their Flextome product. It has leveraged its leading position in the drug-eluting stent market in order to negotiate combined contracts with hospitals and group purchasing organizations (GPOs). Other competitors include Abbott Laboratories, Medtronic, AngioScore, Cordis, Atrium Medical, and Volcano Corp.

Editor’s note: The information contained in this article derives from a detailed and comprehensive report published by iData Research entitled U.S. Interventional Cardiology Devices Market. This is part of a series of publications by the same title for Japan and 15 European countries. For more information, visit idataresearch.com.

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init